Brief: SynAct Explores Conditions For Carrying Out Directed Share Issue

SynAct Pharma AB

05/02/2021 09:00

Feb 5  (Reuters) - SynAct Pharma AB  SYNACT.TE :  
    * SAID ON THURSDAY INTENDS TO CARRY OUT A DIRECTED NEW SHARE
ISSUE
OF UP TO SEK 55 MILLION, DIRECTED AT QUALIFIED INVESTORS IN
SWEDEN AND INTERNATIONALLY, WITH DEVIATION FROM EXISTING
SHAREHOLDERS' PREFERENTIAL RIGHTS
    * SUBSCRIPTION PRICE FOR THE NEW SHARES IN THE DIRECTED
SHARE
ISSUE WILL BE DETERMINED THROUGH AN ACCELERATED BOOKBUILDING
PROCEDURE
    * INTENDS TO USE THE PROCEEDS FROM THE DIRECTED SHARE ISSUE
TO
REACH THE ALREADY ANNOUNCED MILESTONES FOR ITS PHASE IIA STUDIES
IN RHEUMATOID ARTHRITIS (RA), NEPHROTIC SYNDROME AND COVID-19
(ARDS), AND BE ABLE TO PREPARE FOR AND COMPLETE A PHASE IIB
STUDY IN RA

    
 Source text for Eikon:  urn:newsml:reuters.com:*:nWkr7dNv8k
    
 Further company coverage:  SYNACT.TE  
   
    
   

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))